Shahrokh F. Shariat

1 month ago | acsjournals.onlinelibrary.wiley.com | Wataru Fukuokaya |Keiichiro Mori |Takafumi Yanagisawa |Fumihiko Urabe |Pawel Rajwa |Alberto Briganti | +4 more

Sep 12, 2024 | nature.com | Akihiro Matsukawa |Takafumi Yanagisawa |Marcin Miszczyk |Ichiro Tsuboi |Ekaterina Laukhtina |Juan Rivas | +4 more

AbstractRecent advancements in the management of biochemical recurrence (BCR) following local treatment for prostate cancer (PCa), including the use of androgen receptor signaling inhibitors (ARSIs), have broadened the spectrum of therapeutic options. We aimed to compare salvage therapies in patients with BCR after definitive local treatment for clinically non-metastatic PCa with curative intent.

May 30, 2024 | nature.com | Andrea Mari |Anna Cadenar |Simone Albisinni |Riccardo Autorino |Fabrizio Di Maida |M. Carmen Mir | +6 more

AbstractPositron Emission Tomography-Computed Tomography using Prostate-Specific Membrane Antigen (PSMA PET/CT) is notable for its superior sensitivity and specificity in detecting recurrent PCa and is under investigation for its potential in pre-treatment staging. Despite its established efficacy in nodal and metastasis staging in trial setting, its role in primary staging awaits fuller validation due to limited evidence on oncologic outcomes.

Feb 6, 2024 | thelancet.com | Shahrokh F. Shariat

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria Department of Urology, Weill Cornell Medical College, New York, NY, USA Department of Urology, University of Texas Southwestern, Dallas, TX, USA Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan Research Center for Evidence...

Nov 17, 2023 | nature.com | Ekaterina Laukhtina |Shahrokh F. Shariat

Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the current standard therapy for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A phase II trial testing treatment intensification by adding the immune-checkpoint inhibitor nivolumab to chemotherapy has yielded promising complete response rates, which suggests that bladder-preserving treatment could become attainable in selected patients.